Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease

    Cochrane Database of Systematic Reviews Date published:

  • Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

    The Lancet Diabetes & Endocrinology Date published:

  • Letter by Matthews et al Regarding Article, “Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist”

    Circulation Date published:

  • Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

    Circulation Date published:

  • Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease

    Diabetes Date published:

  • Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial

    Diabetes Date published:

  • Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review

    Diabetes Research and Clinical Practice Date published:

  • Renal trials in diabetes need a platform: time for a global approach?

    The Lancet Diabetes & Endocrinology Date published:

  • Baseline characteristics and enrichment results from the SONAR trial

    Diabetes, Obesity and Metabolism Date published:

  • Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease

    Clinical Journal of the American Society of Nephrology Date published:

  • Abstract #233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program

    Endocrine Practice Date published:

  • Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

    Cardiovascular Diabetology Date published:

  • Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

    European Heart Journal Date published:

  • Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

    Diabetes, Obesity and Metabolism Date published:

  • Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology

    Kidney International Supplements Date published:

  • Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

    Circulation Date published: